These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23847045)

  • 1. Novel conjugation of tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) with monomethyl auristatin E for efficient antitumor drug delivery.
    Pan LQ; Wang HB; Xie ZM; Li ZH; Tang XJ; Xu YC; Zhang C; Naranmandura H; Chen SQ
    Adv Mater; 2013 Sep; 25(34):4718-22. PubMed ID: 23847045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing Multistep Delivery of PEGylated Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand-Toxin Conjugates for Improved Antitumor Activities.
    Wei X; Yang X; Zhao W; Xu Y; Pan L; Chen S
    Bioconjug Chem; 2017 Aug; 28(8):2180-2189. PubMed ID: 28697305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities.
    Pan LQ; Zhao WB; Lai J; Ding D; Wei XY; Li YY; Liu WH; Yang XY; Xu YC; Chen SQ
    Sci Rep; 2015 Oct; 5():14872. PubMed ID: 26445897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E.
    Wang Y; Zhang X; Fan J; Chen W; Luan J; Nan Y; Wang S; Chen Q; Zhang Y; Wu Y; Ju D
    Front Immunol; 2018; 9():1799. PubMed ID: 30123222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reductively cleavable polymer-drug conjugates based on dendritic polyglycerol sulfate and monomethyl auristatin E as anticancer drugs.
    Rades N; Achazi K; Qiu M; Deng C; Haag R; Zhong Z; Licha K
    J Control Release; 2019 Apr; 300():13-21. PubMed ID: 30794827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.
    Lee AL; Dhillon SH; Wang Y; Pervaiz S; Fan W; Yang YY
    Mol Biosyst; 2011 May; 7(5):1512-22. PubMed ID: 21350763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels.
    Temming K; Meyer DL; Zabinski R; Dijkers EC; Poelstra K; Molema G; Kok RJ
    Bioconjug Chem; 2006; 17(6):1385-94. PubMed ID: 17105215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Recombinant Circularly Permuted Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) (Recombinant Mutant Human TRAIL) in Combination with 5-Fluorouracil in Human Colorectal Cancer Cell Lines HCT116 and SW480.
    Sun T; Zhu T; Liang X; Yang S; Zhao R
    Med Sci Monit; 2018 Apr; 24():2550-2561. PubMed ID: 29695684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved antitumor activity of TRAIL fusion protein via formation of self-assembling nanoparticle.
    Huang K; Duan N; Zhang C; Mo R; Hua Z
    Sci Rep; 2017 Feb; 7():41904. PubMed ID: 28225020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Site-specific PEGylation of a mutated-cysteine residue and its effect on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).
    Pan LQ; Wang HB; Lai J; Xu YC; Zhang C; Chen SQ
    Biomaterials; 2013 Dec; 34(36):9115-23. PubMed ID: 23981355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors.
    Reis CR; van der Sloot AM; Szegezdi E; Natoni A; Tur V; Cool RH; Samali A; Serrano L; Quax WJ
    Biochemistry; 2009 Mar; 48(10):2180-91. PubMed ID: 19236007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand.
    Fang F; Wang AP; Yang SF
    Acta Pharmacol Sin; 2005 Nov; 26(11):1373-81. PubMed ID: 16225761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NanoTRAIL-Oncology: A Strategic Approach in Cancer Research and Therapy.
    Shi Y; Pang X; Wang J; Liu G
    Adv Healthc Mater; 2018 Jun; 7(11):e1800053. PubMed ID: 29527836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sortase A-Generated Highly Potent Anti-CD20-MMAE Conjugates for Efficient Elimination of B-Lineage Lymphomas.
    Pan L; Zhao W; Lai J; Ding D; Zhang Q; Yang X; Huang M; Jin S; Xu Y; Zeng S; Chou JJ; Chen S
    Small; 2017 Feb; 13(6):. PubMed ID: 27873460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
    Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
    Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.
    Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination Nanopreparations of a Novel Proapoptotic Drug - NCL-240, TRAIL and siRNA.
    Riehle R; Pattni B; Jhaveri A; Kulkarni A; Thakur G; Degterev A; Torchilin V
    Pharm Res; 2016 Jul; 33(7):1587-601. PubMed ID: 26951567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
    Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
    J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGF3L fusion enhances the antitumor activity of TRAIL by promoting assembly into polymers.
    Wang Y; Lei Q; Yan Z; Shen C; Wang N
    Biochem Pharmacol; 2018 Sep; 155():510-523. PubMed ID: 30059675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.